|
Aug 11
|
Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth
|
|
Aug 11
|
Non-metastatic Prostate Cancer Market Analysis and Forecast, 2023-2035 | J&J, Astellas, Bristol-Myers Squibb, Pfizer, Merck, Bayer, Sanofi, Clovis, AstraZeneca, AbbVie, and Boehringer Lead Innovations
|
|
Aug 11
|
Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.
|
|
Aug 8
|
C3.ai's Generative AI Surge: A Catalyst for Fiscal 2026 Upside?
|
|
Aug 7
|
The Strong Earnings Posted By Bristol-Myers Squibb (NYSE:BMY) Are A Good Indication Of The Strength Of The Business
|
|
Aug 6
|
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
|
|
Aug 6
|
5% Yields Are Hard to Find. Here Are 4 Dividend Stocks You Can Count On.
|
|
Aug 6
|
Pfizer Pops Despite Looming Pharma Tariffs
|
|
Aug 5
|
Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth
|
|
Aug 5
|
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
|
|
Aug 5
|
Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
|
|
Aug 4
|
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
|
|
Aug 4
|
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
|
Aug 4
|
BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped.
|
|
Aug 4
|
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
|
|
Aug 4
|
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
|
|
Aug 4
|
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
|
|
Aug 3
|
Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
|
|
Aug 2
|
Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Aug 1
|
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
|